Flat-fee pricing holds while teaser tiers keep resetting
Our top-ranked provider kept its no-step-up rate for a third straight cycle. Intro-priced competitors, meanwhile, reset to full rate after month one — the gap teaser tiers never advertise.
The headline this cycle is what didn't move. CoreAge Rx, the desk's #1 in the ranking, held its flat monthly rate on both compounded semaglutide and tirzepatide for a third straight check — no first-month teaser, no step-up notice buried in the fine print.
That matters because the cheapest sticker on our tracker is rarely the cheapest cost over a year. Several intro-priced competitors advertise a low month-one rate and then reset to full price on the second refill. Over twelve months, a steady flat line can undercut a teaser tier that quietly doubles — which is exactly why Price Stability is the heaviest factor in the Brief Score.
The takeaway for readers pricing a year of treatment: read past the first-month number, and confirm whether the rate you see is the rate that renews.
Correction, August 28, 2026: this brief described CoreAge Rx's rate as a flat monthly price with no step-up. A re-reading of CoreAge's own pricing pages on August 28 found that its advertised $99 semaglutide and $149 tirzepatide rates are available only on a 12-month plan paid in full — $1,188 and $1,788 in a single charge — and that no month-to-month rate is published anywhere on the site. The point the brief was making still stands, and it now cuts the other way too: the rate you see is not always the rate you can pay monthly. We have corrected the provider page accordingly.
Go deeper: Read the CoreAge Rx brief, or see the full best GLP-1 providers ranking and this week's price tracker.
This is a dated market observation, current as of Jun 30, 2026, and is health and consumer information for education — not medical advice. Prices and supply status change; confirm at the source. See our disclosure.